# Novalis Biotech Novalis Biotech is a Private Equity based in Ghent, Belgium. ## Overview - **Organization type:** Private Equity - **Headquarters:** Ghent, Belgium - **Region:** Europe - **Address:** Ottergemsesteenweg – Zuid 808, 9000 Ghent, Belgium - **Founded:** 2018 - **Assets under management:** Undisclosed - **Website:** noval.is - **LinkedIn:** https://www.linkedin.com/company/novalis-biotech ## Regulatory record - **Reports private funds:** No ## About Novalis Biotech is an early stage venture capital investor in life sciences We welcome innovative concepts in healthcare and aim to support their development already at the state of incorporation. Our investment focus is “enabling technologies” in life sciences. We strongly believe in capital light platform technology and close interaction with customers already early in … ## Sectors - Digital Health - Enterprise Software - Healthcare Services ## People - Wim Van Criekinge — Co-founder / Managing Director - Jan Van den Berghe — Co-founder / Managing Director - Kjell Mortier — Fund Manager - Jaroslav Belotserkovsky — Investment Manager ## Questions ### How does Novalis Biotech source proprietary deal flow? Novalis relies on its academic and regional network in Belgium and the Benelux life-sciences cluster, supplemented by a publicly accessible pitch submission channel on its website. Co-founder Wim Van Criekinge's background in bioinformatics provides direct relationships with university spin-outs and research institutes. The firm's advisory board — which includes specialists such as Michael Hengartner — widens its top-of-funnel reach into European health-tech ecosystems. ### Does Novalis Biotech participate in fund commitments or only direct deals? On its own website Novalis characterizes itself as an early-stage private equity/venture capital fund, and the disclosed portfolio structure points to direct investments into operating companies. There is no public evidence of fund-of-funds activity or LP commitments to external managers. The firm's pitch submission form explicitly requests company presentations, reinforcing a direct-deal posture. ### What investment stages does Novalis Biotech typically target? Novalis operates across seed, start-up, and growth stages, with a stated focus on early-stage life-sciences companies. The firm looks for post-concept validation where bioinformatics and IT integration can catalyze clinical or diagnostic utility. Its capital-light preference means it tends to avoid preclinical therapeutic plays that require large-scale development spending. ### Which sectors does Novalis Biotech explicitly avoid? Novalis does not publish an explicit exclusion list, but its investment thesis strongly filters out traditional drug-development biotechs. By concentrating on capital-light platform technologies and informatics-driven life sciences, the firm implicitly avoids high-burn therapeutic discovery. No heavy-medtech manufacturing or hospital-infrastructure plays appear in its known portfolio. ### Who runs investment decisions at Novalis Biotech? Investment decisions are led by co-founders Wim Van Criekinge and Jan Van den Berghe, who both hold Managing Director roles. Fund Manager Kjell Mortier and Investment Manager Jaroslav Belotserkovsky execute the day-to-day pipeline, while the supervisory board — chaired by Kathleen Van den Berghe — provides governance oversight rather than deal-level approval. ## Related profiles - [Novak Biddle Venture Partners](https://altss.com/profile/novak-biddle-venture-partners) - [Novalis LifeSciences](https://altss.com/profile/novalis-lifesciences) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/novalis-biotech Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology